Key Highlights
- Shares climbed to a 52-week peak of $225.88, delivering a 61.6% gain year-over-year
- Nykredit A/S initiated an $8.02 million position during the second quarter
- Second quarter earnings per share of $3.60 exceeded analyst expectations of $2.94; sales reached $2.74B
- Wall Street maintains a “Moderate Buy” rating with a consensus target of $230.14
- Wolfe Research boosted its rating to “Outperform” with a $300 target in August
Biogen shares touched a 52-week peak of $225.88 during Monday’s session, extending an impressive rally that has delivered 61.6% gains over the past twelve months.
Tuesday’s trading session saw the stock open at $219.07, advancing approximately 1.7% intraday. The equity is currently trading above its 50-day moving average of $211.20 and well ahead of its 200-day moving average of $198.54.
The stock’s 1-year low of $135.39 highlights the substantial appreciation achieved over the trailing 12-month period.
The biotechnology company commands a market capitalization between $32.37 billion and $33.26 billion, with its price-to-earnings ratio ranging from 38.77 to 39.41 across recent sessions.
Quarterly Results Drive Upward Momentum
The stock’s impressive performance has been supported by robust operational results. During its latest quarterly report, Biogen delivered earnings per share of $3.60, surpassing Wall Street’s consensus forecast of $2.94 by a substantial $0.66 margin.
Total revenue reached $2.74 billion, exceeding analyst projections of $2.46 billion while representing a 3.4% increase compared to the prior year period.
Looking ahead to fiscal 2026, Biogen has issued guidance calling for EPS between $12.00 and $13.00. The Street is currently modeling $12.41 in earnings per share for that fiscal year.
Major institutional investors have been actively accumulating shares. Nykredit A/S established a new position of 37,134 shares during Q2, representing approximately $8.02 million in value.
Several other institutional players expanded their positions as well. Wedbush Securities increased its stake by 5.1% in the second quarter. Rothschild Investment, Meeder Advisory, Kera Capital, and Parallel Advisors all boosted their holdings during the first half of the year.
Institutional ownership now accounts for 87.93% of Biogen’s total shares outstanding.
Wall Street Raises Price Targets
Sell-side analysts have grown increasingly bullish on the stock. Wolfe Research elevated BIIB from “Peer Perform” to “Outperform” in August, establishing a $300 price objective.
Oppenheimer maintained its “Outperform” recommendation while keeping its $300 target intact. Canaccord Genuity increased its price objective from $245 to $248, reiterating a Buy rating.
RBC Capital lifted its target to $260 from $240, highlighting the lupus treatment candidate litifilimab as a significant near-term catalyst. H.C. Wainwright similarly raised its target to $251 from $237, citing the same rationale.
Piper Sandler increased its price objective to $245 from $225, pointing to improved forecasts for multiple products including Vumerity and Syfovre. Stifel maintains a Buy recommendation with a $242 target.
Across 33 analysts covering the stock, the consensus rating stands at “Moderate Buy,” with an average price target of $230.14.
According to InvestingPro’s Fair Value analysis, the shares may still be trading below their intrinsic value at present levels.
The company recently announced plans to implement Veeva Systems’ Vault CRM across its global operations, a strategic move that Raymond James analysts noted aligns with broader pharmaceutical industry trends.
Phase 3 clinical trial data for litifilimab in lupus is anticipated later in 2025, with Stifel among the firms expressing optimism about the potential outcomes.
The post Biogen (BIIB) Stock Surges to New 52-Week Peak on Earnings Beat and Analyst Optimism appeared first on Blockonomi.
